InvestSMART

Acrux Limited (ASX: ACR) - Announcements

- Current share price for ACR : $0.009

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5 Acrux commences Phase 3 trial of Testosterone MD-Lotion 24 Jun 2008 10:45AM $1.010 $0.009 fallen by 99.11%
$5 Acrux Chairman Repurchases 3.3 Million Shares 20 Jun 2008 9:44AM $1.010 $0.009 fallen by 99.11%
$5 Appendix 4C - Quarterly Cash Flow Report 28 Apr 2008 12:18PM $0.805 $0.009 fallen by 98.88%
$5 Response to ASX Query 11 Apr 2008 5:21PM $0.850 $0.009 fallen by 98.94%
$5 Share ownership dispute - further information 8 Apr 2008 1:04PM $0.830 $0.009 fallen by 98.92%
$5 VIVUS agreement with FDA on testosterone spray Phase 3 trial 3 Apr 2008 2:04PM $0.850 $0.009 fallen by 98.94%
$5 Share ownership dispute 3 Apr 2008 10:28AM $0.870 $0.009 fallen by 98.97%
$5 Half Year Accounts and Appendix 4D 25 Feb 2008 9:22AM $0.760 $0.009 fallen by 98.82%
$5 Compelling results of Testosterone MD-Lotion market research 20 Feb 2008 8:58AM $0.980 $0.009 fallen by 99.08%
$5 Appendix 4C - Quarterly Cash Flow Report 30 Jan 2008 9:57AM $1.190 $0.009 fallen by 99.24%
$5 Fentanyl MDTS Phase 1 trial results 25 Jan 2008 8:30AM $1.150 $0.009 fallen by 99.22%
$5 Start of phase 3 trial with first animal health product 14 Nov 2007 9:38AM $1.350 $0.009 fallen by 99.33%
$5 Positive trial results and progress on testosterone lotion 13 Nov 2007 10:31AM $1.525 $0.009 fallen by 99.41%
$5 New Drug Application for Ellavie Submitted for Review by TGA 12 Nov 2007 11:56AM $1.340 $0.009 fallen by 99.33%
$5 Successful clinical trial with nicotine spray 8 Nov 2007 8:32AM $1.310 $0.009 fallen by 99.31%
$5 Appendix 4C - Quarterly Cash Flow Report 30 Oct 2007 9:09AM $1.345 $0.009 fallen by 99.33%
$5 Full Year Statutory Accounts 30 Aug 2007 10:01AM $1.360 $0.009 fallen by 99.34%
$5 Acrux Receives US$3 Million Milestone Payment for Evamist 28 Aug 2007 9:24AM $1.350 $0.009 fallen by 99.33%
$5 Acrux IND for Fentanyl MDTS Accepted by FDA 1 Aug 2007 10:04AM $1.550 $0.009 fallen by 99.42%
$5 Estradiol spray approved by FDA 31 Jul 2007 10:20AM $1.500 $0.009 fallen by 99.40%
$5 Reinstatement to Official Quotation 18 Jul 2007 10:15AM $1.700 $0.009 fallen by 99.47%
$5 Completion of $22.5 million Capital Raising 18 Jul 2007 10:15AM $1.700 $0.009 fallen by 99.47%
$5 Suspension and request 16 Jul 2007 9:27AM $1.720 $0.009 fallen by 99.48%
$5 Positive results in Phase 2 trial of Testosterone MD-Lotion 16 Jul 2007 9:15AM $1.720 $0.009 fallen by 99.48%
$5 Trading halt 12 Jul 2007 9:11AM $1.720 $0.009 fallen by 99.48%

626 - 650 of 693 results

Page 26 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.